Pfizer stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

European equities traded in the US as American depositary receipts were moving lower late Friday morning, declining 0.85% to 1,302.64 on the S&P Europe Select ADR Index, which is down about 2.8% for ...

The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

Robert F. Kennedy Jr. would create "significantly more volatility" in health markets if he is confirmed as Secretary of Health and Human Services, making navigating policy risks far more challenging, ...

Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.